A single dose of N-methyl-N-nitrosourea given to sexually immature female Buf/N rats produces a high incidence of mammary adenocarcinomas. A large percentage of these tumors contain the Ha-ras oncogene, activated by a G -3 A transition at the second nucleotide of codon 12. Copenhagen rats, on the other hand, are completely resistant to mammary tumor induction by a number of carcinogens, including N-methyl-N-nitrosourea. Here we show, using a sensitive method involving PCR, that codon 12 Ha-mrs mutations occur in the mammary glands of both Buf/N and Copenhagen rats 30 days after N-methyl-N-nitrosourea treatment. These mutations were evenly distributed among individual mammary glands and were present in purified mammary epithelial cells.
allele increased by a factor of 10-100 between 30 and 60 days, whereas in Copenhagen rats, there was no such increase during this time period. We conclude that the resistance of the Copenhagen rat to mammary carcinogenesis is not due to a defect in initiation but rather appears to be due to the inability of cells containing a mutated ras allele to undergo sustained clonal expansion.
N-Methyl-N-nitrosourea (MNU) induces a high incidence of mammary adenocarcinomas in a number of strains of rats (1) . Even a single dose given to sexually immature (50-day-old) animals is sufficient to induce these tumors (2, 3) . The Ha-ras oncogene, activated by a G --A transition mutation at the second nucleotide of codon 12, is found in >85% of the tumors (3, 4) . MNU is known to form 06-methylguanine in DNA, leading to G -* A transitions during DNA replication (5, 6) . Since MNU has a half life of <1 hr under physiological conditions (7) , its mutagenic effects must occur within a short time after its administration. It has been suggested, therefore, that the Ha-ras gene is activated during the initiation of carcinogenesis (3, 4) . In support of this notion, Kumar et al. (8) have shown the presence of an activated Ha-ras gene in mammary gland DNA as early as 2 weeks after administration of MNU to neonatal rats, which is at least 2 months before the onset of neoplasia. Furthermore, Wang et al. (9) recently demonstrated carcinoma induction after direct infusion into the central mammary duct of a replication-defective retrovirus containing v-Ha-ras.
Susceptibility to mammary gland carcinogenesis varies considerably, however, in different strains of rat. Buf/N rats, for example, are highly susceptible, developing multiple mammary tumors after a single injection of MNU at 50 days of age (3) . Copenhagen rats, on the other hand, are completely resistant to mammary adenocarcinoma induction by a number of carcinogens, including MNU (10, 11) . Promotion of carcinogenesis in susceptible animals is thought to be caused by the proliferation of initiated cells stimulated by estrogen-induced mammary gland development (12) (13) (14) . Ovariectomy prior to or after carcinogen administration reduces mammary tumor development to negligible levels (1, 8) , whereas administration of estrogens to the ovariectomized animals leads to tumor formation (8) . Therefore, one possible factor leading to resistance in the Copenhagen rat might be estrogen deficiency. Isaacs (11) has demonstrated, however, that there is no difference between susceptible and resistant rats in a series of factors, including host and mammary gland growth rates, between 20 and 200 days of age. Isaacs also demonstrated that at 50 days of age, both susceptible and resistant rats are continuously proceeding through the estrous cycle; there are no differences in 17X3-estradiol, progesterone, or prolactin levels at any point in their cycles (11) . Breeding experiments in which resistant Copenhagen rats were crossed with highly susceptible inbred strains suggest that a single autosomal dominant tumor suppressor gene in the mammary parenchyma ofCopenhagen rats confers resistance to MNU-induced mammary carcinogenesis in the hybrids (10, 11, 15, 16) . However, the molecular basis of the resistance of Copenhagen rats, including the stage at which the putative tumor suppressor gene blocks mammary carcinogenesis, is not known.
To understand the molecular basis of the resistance of the Copenhagen rat to mammary carcinogenesis, we began our studies by investigating DNA methylation in rats treated with MNU. We showed that the kinetics of formation and repair of 06-methylguanine in DNA from mammary gland epithelial cells is essentially identical in the Buf/N and Copenhagen rat (unpublished data). Furthermore, we showed that the extent of methylation by MNU of a restriction fragment containing exons The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. glands or mammary epithelial cells by the method ofMiller et aL (17) . Briefly, the excised mammary glands were pulverized in liquid nitrogen and then digested with Pronase in the presence of 2% sodium dodecyl sulfate. After proteins were precipitated by salt, DNA was obtained by precipitation with ethanol. Mammary epithelial cells were prepared by digestion with collagenase as described by Fong et al. (18) .
Analysis of Ha-ras Mutations. A G -+ A transition mutation at the second guanosine of codon 12 of the Ha-ras gene eliminates an MnI I recognition sequence (4) . Therefore, DNA samples (-1 ,ug) from individual mammary glands were first digested with Mni I (2 units; New England Biolabs) to enrich the preparation in the mutant Ha-ras allele. Mutant Ha-ras sequences were then detected by the PCR/liquid hybridization and gel retardation assay described by Kumar and Barbacid (19) with some modifications. We used Vent DNA polymerase (New England Biolabs) instead of Taq polymerase. Before the addition of the template DNA and polymerase, the mixtures containing 100 1A of 20 mM Tris, pH 8.8/10 mM KCI/10 mM (NH4)2SO4/0.1% Triton X-100/ 100 .ug of bovine serum albumin per ml/6 mM MgSO4/0.2 mM of each dNTP/0.25 .M of each primer were irradiated with 254-nm and 300-nm UV light for 20 min to eliminate any contaminating DNA (20) . Thirty cycles of polymerization were carried out in a Perkin-Elmer/Cetus thermal cycler machine. The times for denaturation, annealing, and polymerization were 1, 2, and 3 min at 940C, 620C, and 720C, respectively. The polymerization time increased by 5 sec per cycle. The primers were 5'-ACCCCTGTAGAAGCGAT-GAC-3' and 5'-AGGGACTC'TTTCGAACGCC-3' (8) . The 3' primer contained the two mismatched bases indicated in bold, which together with a G -* A mutation at codon 12, create an Xmn I restriction site in the mutant allele. The PCR product of both the normal and mutant alleles is a 71-basepair (bp) allele in the presence of a large excess of the normal allele. Our method was based on the method of Kumar and Barbacid (19) that utilized PCR amplification with a liquid hybridization and gel retardation assay. We found, however, that Taq DNA polymerase lacked the required fidelity, creating false positives in control DNA samples. Other researchers have also described this problem (21, 22) . Therefore, we used Vent DNA polymerase that contains a 3'-to-5' exonuclease activity, thereby increasing the fidelity of DNA replication compared with Taq polymerase (23) . Furthermore, since a G A transition in codon 12 of the Ha-ras gene eliminates the GAGG sequence recognized by the restriction endonuclease Mnl I (4), we enriched our samples in the mutant allele by an Mnl I digestion prior to PCR amplification. This step increased the detection limit of our method by about an order of magnitude (data not shown). Finally, our PCR mixtures were irradiated with UV light (254 and 300 nm) for 20 min prior to adding the genomic DNA and polymerase. Such UV treatment has been shown to eliminate most sources of contamination (20) .
The calibration gel shown in Fig. 1 illustrates our method using known dilutions in DNA from normal mammary glands of DNA from a rat mammary adenocarcinoma cell line that contains a mutated Ha-ras gene. In addition to detecting simply the presence of low levels of Ha-ras mutations, we were able to estimate the fraction of cells containing a mutant allele in individual glands (hereafter referred to as the mutant cell fraction). These fractions were estimated visually to the nearest order of magnitude with the aid of standards of tumor cell line DNA diluted in normal DNA run on each gel. Fig. 1 illustrates that the detection limit of the method was a mutant cell fraction of about 10-5, while fractions higher than about lo-, gave a nonlinear response. When the entire method was replicated with DNA from the same glands, reproducible band intensities were obtained. Gels loaded with smaller amounts of PCR product than those illustrated in Figs. [2] [3] [4] confirmed the presence of approximately equal amounts of the normal Ha-ras allele in each lane over the range of observed mutant cell fractions (10-5-10-3).
Fifty-day-old female Buf/N and Copenhagen rats were injected intravenously with a single dose of either 30 or 50 mg of MNU per kg-regimens known to produce a high yield of mammary tumors in Buf/N and other susceptible rats (2, 3) but no such tumors in Copenhagen animals (10, 11) . Individual mammary glands were excised and analyzed for Ha-ras mutations 30 or 60 days after treatment. At these times, the glands were macroscopically normal. Fig. 2A (Fig. 2B) . Table 1 summarizes the data from a large number of such analyses. None of 24 glands from control Buf/N rats showed a codon 12 mutation at 30 days and none of 16 at 60 days after treatment. Only one rat treated with 30 mg of MNU per kg and analyzed 30 days later had no positive glands; in all other cases, individual rats had at least one positive gland. A larger fraction of the glands was positive at the higher MNU dose. Furthermore, there were no glands after 30 days, even at an MNU dose of 50 mg/kg, in which the mutant cell fraction was >10-5, whereas after 60 days, 5 of 32 glands had fractions of 10-1_0-4, 1 gland had a fraction of 10-4-l03, and 1 had a fraction of >10-3. The distribution of mammary glands containing a mutant Ha-ras gene is shown in Table 2 . It is clear that the Ha-ras mutations were rather uniformly distributed amongst the three thoracic and three inguinal pairs of glands. Within these pairs, the distribution was also uniform (data not shown). Fig. 3 and Tables 1 and 2 present the data for Copenhagen rats. It is clear from Fig. 3 and Table 1 control Copenhagen rats showed a codon 12 mutation at 30 days, and none of 16 showed it at 60 days. All MNU-treated rats at both 30 and 60 days had at least one mammary gland containing mutant cells. Furthermore, like the Buf/N rats, a larger fraction of glands from Copenhagen rats were positive at the higher MNU dose and the longer time period (Table 1 ). The distribution of the mutated gene among the Copenhagen glands was uniform (Table 2 ). However, a major difference between the two strains was that in the Copenhagen rats, the mutant cell fraction showed no increase between 30 and 60 days (highest value at either time was 10-5-10-4), whereas in the Buf/N rats, there was a clear increase in the mutant cell fraction during this time period in some of the glands. Mammary epithelial cells were purified from both Buf/N and Copenhagen mammary glands 60 days after treatment with 50 mg of MNU per kg. Ha-ras mutations were present in DNA from cells of both strains (Fig. 4) (24) using pubescent F344 rats, who were also able to detect Ha-ras mutations 3 weeks after MNU treatment in DNA isolated from whole mammary glands. However, our results extend these observations in three areas. First, we have shown that the fraction of cells in several glands containing a mutated Ha-ras allele increases by a factor of 10-100 between 30 and 60 days, undoubtedly because of clonal expansion of the initiated cell population stimulated by gland development (12) (13) (14) . This is in accord with the high susceptibility of the Buf/N rat to mammary carcinogenesis.
Second, the sensitivity ofour method for analysis ofHa-ras mutations allowed us to examine individual mammary glands. Although tumor formation predominates in the thoracic glands (pairs 1-3) (1), we saw no evidence for the preferential formation of Ha-ras mutations in these glands. Sixty days after treatment, however, the incidence of glands having mutant cell fractions >10-5 was higher in the thoracic glands than in the inguinal glands (pairs [4] [5] [6] . This suggests that the expansion of the initiated cell population is stimulated to a greater extent in the target glands for tumor formation.
Third, we have shown that Ha-ras mutations are present in epithelial cells purified from individual mammary glands. The incidence of mutations and the magnitude of the mutant cell fractions in DNA from the purified cells were similar to those in DNA from whole glands. These results are consistent with the cellular origin of mammary tumors in this model. Ade- nocarcinomas of the alveolar or ductal epithelial cells predominate; fibrosarcomas also occur but to a minor extent (1) .
Our analysis of DNA from the mammary glands of Copenhagen rats clearly shows the presence of mutated Ha-ras alleles 30 and 60 days after treatment. Indeed, the incidence and distribution of Ha-ras mutations in the resistant Copenhagen rat are comparable in many respects to those in the susceptible Buf/N rat. Also, like the Buf/N rat, the ras mutations are present in purified mammary epithelial cells. A strong case has been made that Ha-ras genes are directly activated by MNU during the initiation of neoplasia (3, 4, 8) . Since the Copenhagen rat is totally resistant to MNU-induced mammary adenocarcinoma formation (10, 11) , our results show that the resistance is not caused by a defect in initiation. Furthermore, our results provide a molecular basis for the notion suggested by the breeding and transplantation experiments of Isaacs (10, 11, 15) Proc. NatL Acad. Sci. USA 89 (1992) glands from the Buf/N rats, indicating that the expansion of initiated cells is being promoted. During this period in the Copenhagen rats, however, the growth of initiated cells appears to be suppressed, since all glands containing a mutated Ha-ras gene had a mutant cell fraction of <10-5. The drop in the mutant cell fraction in these animals during the 30-to 60-day period may be due to the loss of cells from a terminally differentiating population.
A number of genetic studies have led to the prediction that the mammary tumor suppressor gene that is active in the resistant strains is functionally inactivated in the germ lines of highly susceptible strains (10, 11, 15, 16) . In addition, there is evidence that susceptible animals carry several independently segregating, dominant, autosomal susceptibility genes, while strains of intermediate susceptibility carry neither suppressor nor susceptibility genes (16, 25, 26) . It is not clear how the suppressor gene in the Copenhagen rat is protected from inactivation by carcinogen exposure, especially since it has been shown that even multiple treatments with MNU do not lead to tumors (10) . Indeed, our finding that these animals are initiated by MNU treatment suggests that there may be treatment regimes that result in the inactivation of the suppressor gene with subsequent tumor growth.
In summary, we have shown the presence of Ha-ras codon 12 mutations in the mammary glands of both susceptible Buf/N and resistant Copenhagen-rats 30-60 days after MNU treatment. Therefore, the resistance of the Copenhagen rat to mammary carcinogenesis is not due to a defect in initiation but rather appears to be due to the inability of cells containing a mutated ras allele to undergo sustained clonal expansion. While estrogens are promoters, they are present at similar levels in both resistant and susceptible animals. Therefore, uncharacterized suppressor and/or susceptibility genes appear to control strain-dependent mammary tumor development.
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